Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.41 |
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | CDK7 | P50613 | 8/20 | 0.41 |
| ▸ | CCNH | P51946 | 8/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.41 |
| ▸ | CCNK | O75909 | 5/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360275 | 1.00 | CCNA2 (0.41) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360471 | 1.00 | CCNA2 (0.41) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360632 | 0.87 | CCNK (0.44) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360581 | 0.87 | PIK3CD (0.40) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360582 | 0.87 | PIK3CD (0.40) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360667 | 0.87 | CCNK (0.44) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL23360630 | 0.87 | CCNK (0.44) | CCNA2CDK2CDK7CCNHMNAT1 | |
| SCHEMBL28834176 | 0.85 | PIK3CD (0.51) | PIK3CD | |
| SCHEMBL29862916 | 0.85 | PIK3CD (0.51) | PIK3CD | |
| SCHEMBL28834077 | 0.85 | PIK3CD (0.51) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | CCNA2 3851/4885CDK2 1830/4885CDK7 2559/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | CCNA2 3851/4885CDK2 1830/4885CDK7 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.